Gemtuzumab ozogamicin: A component of induction therapy in AML?

Francis Giles

doi:10.1016/j.leukres.2004.06.010

Gemtuzumab ozogamicin: A component of induction therapy in AML?

Francis Giles

Department of Cancer Biology

Research output: Contribution to a Journal (Peer & Non Peer) › Editorial

1 Citation (Scopus)

Original language	English
Pages (from-to)	1-2
Number of pages	2
Journal	Leukemia Research
Volume	29
Issue number	1
DOIs	https://doi.org/10.1016/j.leukres.2004.06.010
Publication status	Published - Jan 2005
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.leukres.2004.06.010

Cite this

@article{d89b7df7a1154a57808432b9dc6cd649,

title = "Gemtuzumab ozogamicin: A component of induction therapy in AML?",

author = "Francis Giles",

year = "2005",

month = jan,

doi = "10.1016/j.leukres.2004.06.010",

language = "English",

volume = "29",

pages = "1--2",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "1",

}

TY - JOUR

T1 - Gemtuzumab ozogamicin

T2 - A component of induction therapy in AML?

AU - Giles, Francis

PY - 2005/1

Y1 - 2005/1

UR - https://www.scopus.com/pages/publications/8444225377

U2 - 10.1016/j.leukres.2004.06.010

DO - 10.1016/j.leukres.2004.06.010

M3 - Editorial

C2 - 15541468

AN - SCOPUS:8444225377

SN - 0145-2126

VL - 29

SP - 1

EP - 2

JO - Leukemia Research

JF - Leukemia Research

IS - 1

ER -

Gemtuzumab ozogamicin: A component of induction therapy in AML?

UN SDGs

Access to Document

Other files and links

Cite this